复星医药：控股子公司与Expedition签署许可协议

Core Viewpoint - Fosun Pharma has signed a licensing agreement with Expedition for the development, production, and commercialization of the investigational product XH-S004 outside of China and Hong Kong, while retaining rights for these regions [1] Group 1: Licensing Agreement Details - The agreement grants Expedition global rights to develop and commercialize XH-S004, excluding China and Hong Kong [1] - Fosun Pharma retains the rights to develop, produce, and commercialize the product within China and Hong Kong [1] Group 2: Product Information - The investigational drug XH-S004 has potential indications for non-cystic fibrosis bronchiectasis and chronic obstructive pulmonary disease (COPD) [1] Group 3: Financial Terms - Expedition will pay up to $120 million in non-refundable upfront payments to Fosun Pharma [1] - Additional payments will be made based on development and regulatory milestones [1] - Up to $525 million in sales milestone payments will be contingent on annual net sales performance of the licensed product in the designated regions [1]